Iniparib, also known as 4-Iodo-3-nitrobenzamide BSI-201, is a chemical compound that has gained considerable attention for its potential therapeutic effects on a variety of health conditions. It is an experimental cancer treatment that has shown promising results in clinical trials, and has been the subject of extensive research due to its potential cytotoxic effects on cancer cells.
Chemical Name: 4-Iodo-3-nitrobenzamide Molecular Formula: C7H4IN2O3 Formula Weight: 306.02 g/mol CAS No: 160003-66-7
Top ten keywords from Google:
- Cancer treatment
- PARP inhibitors
- DNA damage
- Clinical trials
- BRCA1/2 mutation
- Triple-negative breast cancer
- Ovarian cancer
- Non-small cell lung cancer
- 4-Iod-3-nitro-benzamid [German]
- Benzamide, 4-iodo-3-nitro-
Health Benefits of Iniparib:
Iniparib may offer a number of potential health benefits, particularly for those suffering from certain types of cancer. It works by inhibiting the enzymatic activity of a protein known as PARP, which plays a key role in DNA repair. By blocking this activity, Iniparib can make cancer cells more susceptible to chemotherapy and other treatments.
Potential Effects of Iniparib:
The potential effects of Iniparib are primarily related to its cytotoxicity against cancer cells. It has been shown to be particularly effective against triple-negative breast cancer, ovarian cancer, and non-small cell lung cancer. Iniparib has also been studied for its potential to kill cancer stem cells, which are notoriously difficult to target with traditional cancer therapies.
Iniparib's mechanism of action is primarily through inhibiting the enzymatic activity of PARP, which plays a key role in DNA repair. By blocking this activity, Iniparib can make cancer cells more susceptible to chemotherapy and other treatments. It has also been shown to be effective at inducing autophagy in cancer cells, which can lead to cell death.
While Iniparib has been shown to be relatively safe in clinical trials, there are some potential safety risks associated with its use. Some of the most common side effects of Iniparib use include fatigue, nausea, vomiting, and diarrhea. Additionally, there have been reports of hematological toxicity, including anemia and neutropenia, which may require dose adjustments or discontinuation of treatment.
In addition to the potential safety risks associated with Iniparib use, there are also several potential side effects that may occur. These may include:
The dosing information for Iniparib may vary depending on a number of factors, including the patient's age, weight, and overall health. It is typically administered intravenously, with doses ranging from 5 to 20 mg/kg every three weeks.
Iniparib is an experimental cancer treatment that has shown promise in clinical trials. Its mechanism of action involves inhibiting the enzymatic activity of PARP, which makes cancer cells more susceptible to chemotherapy and other treatments. While Iniparib has been shown to be relatively safe, there are some potential safety risks and side effects associated with its use. Despite these risks, Iniparib continues to be studied for its potential to improve cancer treatment outcomes and improve the quality of life for cancer patients.